Showing 1,241 - 1,260 results of 13,486 for search '(( significantly ((larger decrease) OR (greater decrease)) ) OR ( significant increase decrease ))', query time: 0.40s Refine Results
  1. 1241
  2. 1242
  3. 1243
  4. 1244

    Summary of study eligibility criteria. by Biban Gill (1473337)

    Published 2025
    “…Considering the high prevalence of BV among African, Caribbean and Black (ACB) women, we conducted a prospective, randomized, open-label phase 1 clinical trial to determine the feasibility, safety and tolerability of administering low-dose estrogen, probiotics or both in combination to improve vaginal health and decrease HIV-1 susceptibility.</p><p>Methods</p><p>ACB women aged 18–49 from the Greater Toronto Area (GTA) were randomized to one of four study arms: intravaginal estradiol (Estring©; 7.5mg/day); a vaginal probiotic (RepHresh™ Pro-B™) administered twice daily; a combination of Estring© and vaginal RepHresh™ Pro-B™ (twice daily); or the Estring© and oral RepHresh™ Pro-B™ (twice daily), for a duration of 30 days. …”
  5. 1245

    Summary of study participation and feasibility. by Biban Gill (1473337)

    Published 2025
    “…Considering the high prevalence of BV among African, Caribbean and Black (ACB) women, we conducted a prospective, randomized, open-label phase 1 clinical trial to determine the feasibility, safety and tolerability of administering low-dose estrogen, probiotics or both in combination to improve vaginal health and decrease HIV-1 susceptibility.</p><p>Methods</p><p>ACB women aged 18–49 from the Greater Toronto Area (GTA) were randomized to one of four study arms: intravaginal estradiol (Estring©; 7.5mg/day); a vaginal probiotic (RepHresh™ Pro-B™) administered twice daily; a combination of Estring© and vaginal RepHresh™ Pro-B™ (twice daily); or the Estring© and oral RepHresh™ Pro-B™ (twice daily), for a duration of 30 days. …”
  6. 1246

    NPF-NPFR pathway in LNd-LPN feedback circuit fine-tune cooling induced locomotion increase. by Xin Yuan (174619)

    Published 2024
    “…(C, D) Optogenetic activation of LNds using CsChrimson (<i>DvPdf-Gal4>Uas-CsChrimson</i>, red line) decreases sleep and this decrease effect was enhanced by NPF RNAi (<i>DvPdf-Gal4>Uas-CsChrimson; Uas-NPF RNAi</i>; green line). …”
  7. 1247
  8. 1248
  9. 1249
  10. 1250
  11. 1251
  12. 1252
  13. 1253
  14. 1254
  15. 1255
  16. 1256
  17. 1257
  18. 1258
  19. 1259
  20. 1260